

REVIEW

Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis

YOUSEF ALIMOHAMADI^{1,2}, MOJTABA SEPANDI^{3,4}, MARYAM TAGHDIR^{3,5}, HADISEH HOSAMIRUDSARI⁶

¹ Pars Advanced and Minimally Invasive Medical Manners Research Center, Pars Hospital, Iran University of Medical Sciences, Tehran, Iran; ² Department of Epidemiology & Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran; ³ Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran;

⁴ Department of Epidemiology & Biostatistics, Faculty of Health, Baqiyatallah University of Medical Sciences, Tehran, Iran;

⁵ Department of Nutrition & Food hygiene, faculty of Health, Baqiyatallah University of Medical Sciences, Tehran, Iran;

⁶ Department of Infectious Diseases, Baharloo Hospital, Railway Square, Tehran University of Medical Sciences, Tehran, Iran

Keywords

Clinical symptoms • COVID-19 • Meta-analysis

Summary

Introduction. COVID-19 is an emerging infectious disease. The study about features of this infection could be very helpful in better knowledge about this infectious disease. The current systematic review and meta-analysis were aimed to estimate the prevalence of clinical symptoms of COVID-19 in a systematic review and meta-analysis.

Methods. A systematic review using Medline/PubMed, Scopus, and Google scholar has been conducted. In the current systematic review and meta-analysis, the articles published in the period January 1, 2020, to April 2, 2020, written in English and reporting clinical symptoms of COVID-19 was reviewed. To assess, the presence of heterogeneity, the Cochran's Q statistic, the I² index, and the tau-squared test were used. Because of significant heterogeneity between

the studies the random-effects model with 95% CI was used to calculate the pooled estimation of each symptom prevalence.

Results. The most common symptoms in COVID-19 patients include: Fever 81.2% (95% CI: 77.9-84.4); Cough: 58.5% (95% CI: 54.2-62.8); Fatigue 38.5% (95% CI: 30.6-45.3); Dyspnea: 26.1% (95% CI: 20.4-31.8); and the Sputum: 25.8% (95% CI: 21.1-30.4). Based on the meta-regression results, the sample size used in different studies did not have a significant effect on the final estimate value ($P > 0.05$).

Conclusions. Considering the main symptoms of COVID-19 such as Fever, Cough, Fatigue, and Dyspnea can have a key role in early detection of this disease and prevent the transmission of the disease to other people.

Introduction

The World Health Organization (WHO) described Coronavirus 2019 (COVID-19) as a public health emergency. The international concern of COVID-19 is more in comparison to Severe Acute Respiratory Syndrome (SARS), which previously was pandemic in 2003 [1]. Coronaviruses are important pathogens that can affect the lower respiratory tract in humans and can cause diseases ranging from a simple cold to severe infection with up to 50% lethality [2]. The COVID-19 is a highly contagious infectious disease and one infected person can infect an average of three other people [3] which is higher than that for SARS (1.7-1.9) and MERS (< 1), suggesting that SARS-CoV-2 has a greater potential for being outbreak. Evidence suggests that there are many similarities between COVID-19 and SARS. About 79.5% of the similarities in the genome sequence of these two viruses have been reported [4]. COVID-19 can spread in the community more easily than MERS and SARS because of the less severe clinical picture of it [5]. Although the disease is mild in most people, in some patients, especially those with other underlying diseases, there may be a respiratory failure, arrhythmias,

shock, Kidney failure, cardiovascular damage, or liver failure [6, 7]. Currently, there is no effective antiviral treatment for the disease and only supportive care may be helpful [7] The case fatality rate (CFR) of COVID-19 was reported to be 3.8% but it can differ in patients who have comorbidities [8]. The CFR of COVID-19 is lower than that of SARS and that of MERS[5]. The most common symptoms are fever, cough, and myalgia or fatigue [9]. Although the clinical symptoms of the disease are nonspecific, understanding the symptoms is essential. Patient with fever and upper respiratory tract symptoms with lymphopenia or leukopenia should be considered as suspected [9] Patients may present with diarrhea a few days before the fever. A slight number of patients may report a headache [10]. Diarrhea is more common in SARS [5].

Combining the results of studies that have focused on the prevalence of COVID-19 related symptoms could be helpful in the best identification and diagnosis of infection. Because of the importance of symptoms in the identification of COVID-19 infection the current study was aimed to estimate the prevalence of Clinical Symptoms of COVID-19 in a systematic review and meta-analysis.

Materials and methods

ELIGIBILITY CRITERIA

All articles published in the period January 1, 2020, to April 2, 2020, written in English and reporting clinical symptoms of COVID-19 was reviewed. Review articles as well as articles that lacked original data or reported incomplete data were excluded.

INFORMATION SOURCES AND SEARCH STRATEGY

We conducted a systematic review using Medline/PubMed, Scopus and Google scholar. The following search terms used: “Clinical features”, “COVID-19”, “coronavirus disease 2019”, “coronavirus disease-19”, “2019 novel coronavirus disease”, “severe acute respiratory syndrome coronavirus”, “clinical symptoms”, “clinical characteristics” and “clinical manifestations”. The searches were concluded by April 2, 2020, and two researchers independently assessed search results. References of related papers were also searched for other relevant articles to enhance the search strategy.

STUDY SELECTION

After performing the search strategy some records were excluded because of Duplicates and unrelated. After that, the records screened based on abstracts and titles. The full text of related articles was then assessed according to the inclusion and exclusion criteria. Observational studies that reported clinical symptoms were included in the meta-analysis.

DATA COLLECTION PROCESS AND DATA ITEMS

Data including the type and date of publication, country, the sample size, age, and clinical symptoms of COVID-19 were extracted independently by two authors. A third person checked the article list and data extractions to ensure there were no duplicate articles and also resolved discrepancies about study inclusion.

ASSESSMENT OF METHODOLOGICAL QUALITY

To assess the study quality of the case series studies the Institute of Health Economics (IHE) was used [11]. Also, the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist for observational studies was used assessment quality of the cross-sectional and cohort studies.

META-REGRESSION ANALYSIS

To assess the effect of sample size on pooled estimations the meta-regression analysis was used.

STATISTICAL APPROACH

To assessment, the presence of heterogeneity, the Cochran’s Q statistic, the I² index, and the tau-squared test were used. Due to the difference in the age of patients, we perform subgroup analyzes in different age groups. Because of the presence, the significant heterogeneity between the studies the random-effects model with

95% CI was used to calculate the pooled estimation of symptoms prevalence. The data were analyzed using stata version 11.0.

Results

In the current systematic review and meta-analysis, 54 studies that estimated the symptoms related to COVID-19 were included in the final analysis (Tab. I). After searching PubMed and Google Scholar electronic databases, 1,498 possibly relevant articles were identified; 1,397 articles were removed due to unrelated to study purpose and duplication. Of the remaining 101 articles, 45 were excluded after screening based on abstract and title and 2 articles removed because of lack of needed information. Finally, 54 articles were included in the final meta-synthesis (Fig. 1).

Tab. I. Characteristics of the included studies on effective factors on mortality COVID-19, 2020.

Id	First author	Country	Design	Sample size
1	Dawei Wang [12]	China	Case series	138
2	Chaolin [13]	China	Cross-sectional	41
3	Chen [14]	China	Cross-sectional	99
4	Chung [15]	China	Cross-sectional	21
5	Chen [16]	China	Cross-sectional	29
6	Wang [12]	China	Cross-sectional	138
7	Kui [17]	China	Cross-sectional	137
8	Chang [18]	China	Cross-sectional	13
9	COVID-19 team Australia [19]	Australia	Cross-sectional	15
10	Li et al. [20]	China	Case series	24
11	Feng [21]	China	Case series	21
12	Zhang [22]	China	Case series	9
13	Feng [23]	China	Case series	15
14	Wang [24]	China	Cross-sectional	34
15	Xiaobo[25]	China	Cross-sectional	52
16	Jiong Wu et al. [26]	China	Cross-sectional	80
17	Zonghao Zhao [27]	China	Cross-sectional	77
18	Wen Zhao [28]	China	Cohort study	77
19	Wenjie Yang [29]	China	Cohort study	85
20	Matt Arentz [30]	USA	Case series	21
21	Ying Huang [31]	China	Retrospective	36
22	G Jian-ya Lei Liu [32]	China	Retrospective	51
23	Tao Chen [4]	China	Cohort	274
24	jin Zhang [33]	China	Cross-sectional	242
25	Shijiao Yan [34]	China	Retrospective	168
26	Jian Wu [35]	China	Retrospective	80
27	Yang Xu [36]	China	Retrospective	69
28	Fei Zhou [37]	China	Retrospective	191
29	Zenghui Cheng [38]	China	Retrospectively	11
30	Youbin Liu [39]	China	Retrospective	291
31	Yanli Liu [40]	China	Retrospective	109

continues

follows

Tab. I. Characteristics of the included studies on effective factors on mortality COVID-19, 2020.

32	Yonghao Xu [41]	China	Retrospective	45
33	Lang Wang [42]	China	Cohort	339
34	Zhichao Feng [43]	China	Cohort	141
35	Guo-Qing Qian [44]	China	Retrospective	91
36	BarnabyEdward Young [45]	Singapore	Case series	18
37	Ying Wen [46]	China	Retrospective	417
38	Jiaqiang Liao [47]	China	Retrospective	46
39	Xu Chen [48]	China	Cohort	291
40	Penghui Yang [49]	China	Cohort	55
41	Jie Liu [50]	China	Retrospective	64
42	Hang Fu [51]	China	Cross-sectional	52
43	Heshui Shi [52]	China	Cross-sectional	81
44	Wei Zhao [53]	China	Retrospective	101
45	Hua Fan [54]	China	Cohort	47
46	Ling Hu [55]	China	Retrospective	323
47	X. Zhao [56]	China	Cross-sectional	80
48	Zhaowei Chen [57]	China	Retrospective	89
49	Huijun Chen [58]	China	Retrospective	9
50	Rachael Pung [59]	Singapore	Retrospective	17
51	Wanbo Zhu [60]	China	Retrospective	116
52	Xiaoping Chen [61]	China	Retrospective	123
53	W. Guan [62]	China	Cross-sectional	1,099
54	Xi Xu [63]	China	Retrospective	90

According to the results of the analysis, the most common symptoms in patients with coronavirus include:

- Fever 81.2% (95% CI: 77.9-84.4);
- Cough: 58.5% (95% CI: 54.2-62.8);
- Fatigue: 38.5% (95% CI: 30.6-45.3);
- Dyspnea: 26.1% (95% CI: 20.4-31.8);
- and the presence of Sputum: 25.8% (95% CI: 21.1-30.4).

Other results are shown in Table II and Figure 2. Figure 2 presents the pooled estimation of some symptoms among COVID-19 patients.


META-REGRESSION ANALYSIS

Based on the meta-regression results, the sample size used in different studies did not have a significant effect on the final estimate value ($P > 0.05$).

The distribution of the estimated prevalence of different symptoms according to sample sizes as shown in Figure 3.

The diagrams below show the percentage distribution of symptom estimation based on the volume of different samples.

Based on these charts, the estimated amount of chest pain, cough, dyspnea, hemoptysis, and fever with decreasing sample size showed a decreasing trend, while other symptoms showed an increasing trend with increasing sample size.



Tab. II. The prevalence of different symptoms among COVID-19 patients according to age groups.

Symptom	Number of studies	Sample size	Pooled estimation			I ² (%)	P	T ²
			< 40 years of old	> 40 years of old	Total			
Chest tightness	14	1,967	8.1 (3.7-12.6)	20.1 (9.6-30.6)	17 (13.1-25.4)	96.8	< 0.001	0.01
Cough	54	6,380	53.5 (44.3-62.7)	61.2 (56.3-66.1)	58.5 (54.2-62.8)	91.7	< 0.001	0.02
Diarrhea	36	4,995	3.5 (2.1-4.9)	8.6 (6.5-10.6)	7.6 (5.9-9.2)	83.9	< 0.001	0.001
Dyspnea	27	3,388	8.8 (2.6-15)	31.4 (24-38.7)	26.1 (20.4-31.8)	97.4	< 0.001	0.02
Fatigue	22	3,803	30.5 (21.9-39.1)	38.6 (29.9-47.2)	38.5 (30.6-45.3)	95.5	< 0.001	0.02
Fever	53	5,298	78.1 (73.3-82.8)	83 (79.1-86.9)	81.2 (77.9-84.4)	92.6	< 0.001	0.01
Hemoptysis	9	1,998	1.9 (0-4.6)	1.8 (0.008-2.9)	1.7 (0.008-2.6)	46.9	< 0.001	0.05
Headache	34	5,129	9.2 (5.4-13.1)	9.5 (7.1-12.0)	9.5 (7.5-11.6)	88.7	< 0.001	0.002
Myalgia	37	4,676	19 (14-23.9)	19.4 (14.9-24.0)	20.1 (16.5-23.7)	91.5	< 0.001	0.009
Shortness of breath	13	1,828	17.3 (3.6-30.1)	19.3 (11.2-27.5)	18.5 (12-24.9)	93.3	< 0.001	0.01
Sore throat	29	3,906	15 (9.6-20.4)	14.5 (10.9-18.2)	15 (12.1-18.0)	86	< 0.001	0.004
Sputum production	28	3,677	21 (15.4-26.7)	28 (22-34.1)	25.8 (21.1-30.4)	91	< 0.001	0.01


Discussion

The COVID-19 is a new highly contagious infection that threatens people of all countries [64].

The clinical presentation of COVID-19 is wide, from asymptomatic infection to severe fatal diseases [14]. Considering the shortage of diagnostic kits around the world this systematic review seems necessary, to find the clinical presentation of COVID-19 and using them in early diagnosis of this infection [13]. Unfortunately, there is no treatment for this virus, and patients' treatment is just focused on supportive care. On the other hand, the limited number of critical care centers and mechanical ventilation in the world culminates in high concern for the health care system [7]. To date, over 1,607,912 cases have been reported worldwide and from different countries [65]. To deal with such an emerging infectious disease, there is an urgent need to identify and determine factors associated with the evolution of the disease and its outcomes. In this Systematic Review and Meta-Analysis study, we reported the clinical symptoms of COVID-19. Although the 2019-nCoV sequence is not the same as the other two viruses (SARS-CoV and MERS-CoV) that were pandemic in 2003 and 2012, respectively, they are somewhat similar in pathogenesis [66, 67]. Cytokines may play a role in human coronavirus infection. Indirect evidence suggests that in the second phase of 2019-nCoV infection: high fever, pneumonia, and hypoxemia occur despite a significant reduction in viral load [68]. In this systematic review and meta-analysis study, the clinical symptoms of COVID-19 were examined to provide a better understanding of the disease. The most common

symptoms were fever and, cough, and fatigue that was consistent with the general symptoms of a viral infection and pneumonia. Similar to previous studies [25, 62], the present study showed that fever in 81.2% of cases, cough in 58.5% of cases, and fatigue in 38.5% of cases. Fever is the most common symptom in patients with COVID-19, but not all patients had fever [13, 69]. The fever is an alarming sign of the disease, vomiting, and fever (above 39 degrees) are usually associated with more severe illness and more length of stay in the hospital. Fever is less common in COVID-19 than in SARS and MERS [34, 70]. Therefore, more attention should be paid to COVID-19 patients who do not have fever as a source clue of infection, and if the surveillance system relies only on fever in patients, then some patients will be missed [71]. Diarrhea, myalgia, hemoptysis, and sore throats were less common symptoms in this review, these results were similar to those obtained for other viruses, such as SARS and MERS [26]. This may indicate that COVID-19 can also be classified as a similar infection to SARS and MERS infection, which targets the cells of the lower respiratory tract system. Although nasopharynx is theoretically the first organ infected with the COVID-19, a recent study [13] showed that infected individuals rarely show present upper respiratory symptoms at the onset of the infection. This suggests that the virus mostly targets the cells of the lower respiratory tract cells [72]. Research and clinical findings suggest that SARS-CoV-2 may be colonized in the nasopharynx but the immune system cannot identify COVID-19 in the early stages. Therefore, the virus can be removed from the body with its through natural reactions, including sneezing and runny nose. This demonstrates the importance of accurately

Fig. 2. The forest plots of some symptoms among COVID-19 patients.




identifying COVID-19 symptoms at admission. Especially considering that studies have suggested the possibility of transmission of the disease by a healthy carrier [73]. This may be one of the reasons why COVID-19 is more contagious than SARS.

On the other hand, the lower incidence of early respiratory symptoms may be due to the presence of a pathogenic latency of SARS-CoV-2. Although gastrointestinal symptoms, especially diarrhea, were rare in the current study, the results of a study have shown that the SARS-CoV-2 virus can be isolated from the fecal samples of patients with gastrointestinal symptoms [74]. In another

study, the SARS-CoV-2 virus has been isolated in a rectal swab of patients whose RT-PCR test results were negative with a throat swab sample [44]. Therefore, simultaneously sampling from throat and rectal may be useful, especially in patients with gastrointestinal symptoms. This review has some limitations which should be considered when interpreting the results. Most of the available studies for inclusion are from China. However the present study was done without any language restrictions and based on a comprehensive search strategy, only English electronic databases were searched; thus, it is likely that some related non-English papers have been missed.

Fig. 3. The distribution of estimated prevalence of symptoms according to different sample sizes (the X and Y axes are the sample size and estimated prevalence respectively).



Conclusions

Due to the rapid spreading of this infection, the lack of diagnostic tools, and limited intensive care units in the world, the use of other factors such as the clinical features of COVID19 can serve to give early warning for the appropriate interventions and decrease the number of death of COVID-19. So considering the main symptoms of COVID-19 such as Fever, cough Fatigue and Dyspnea can have a key role in early detection of this disease.

Acknowledgements

We thank all authors involved in this manuscript. Funding sources: this research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of interest statement

The authors declare no conflict of interest.

Authors' contributions

YA and MS formulated the research questions, designed the study, developed the preliminary search strategy, conducted the quality assessment, methodology, formal analysis, prepare drafts of the manuscript, review and editing, MT and HH refined the search strategy by conducting iterative database queries and incorporating new search terms, searched and collected the articles, re-viewed the manuscript content. Data extraction and prepare drafts of the manuscript. All authors critically reviewed the manuscript content. All authors have read and approved the final version of the manuscript.

References

- [1] Bonilla-Aldana D, Dhama K, Rodriguez-Morales AJ. Revisiting the one health approach in the context of COVID-19: a look into the ecology of this emerging disease. *Adv Anim Vet Sci* 2020;8:234-7. <https://doi.org/10.17582/journal.aavs/2020/8.3.234.237>
- [2] Drosten C, Günther S, Preiser W, Van Der Werf S, Brodt H-R, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. *N Engl J Med*. 2003; 348:1967-76. <https://doi.org/10.1056/NEJMoa030747>
- [3] Alimohamadi Y, Taghdir M, Sepandi M. The estimate of the basic reproduction number for novel coronavirus disease (COVID-19): a systematic review and meta-analysis. *J Prev Med Public Health* 2020; 53(3):151-157. <https://doi.org/10.3961/jpmph.20.076>
- [4] Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang HJB. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *bmj* 2020;368. <https://doi.org/10.1136/bmj.m1091>
- [5] Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID-19, SARS and MERS: are they closely related? *Clinical Microbiology and Infection*. 2020;26:729-734. <https://doi.org/10.1016/j.cmi.2020.03.026>
- [6] Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD. How will country-based mitigation measures influence the course of the COVID-19 epidemic? *Lancet*. 2020;395:931-4. [https://doi.org/10.1016/S0140-6736\(20\)30567-5](https://doi.org/10.1016/S0140-6736(20)30567-5)
- [7] Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—an update on the status. *Mil Med Res*.2020;7:1-10. <https://doi.org/10.1186/s40779-020-00240-0>
- [8] Organization WH. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19). 2020.
- [9] Zu ZY, Jiang MD, Xu PP, Chen W, Ni QQ, Lu GM, Zhang LJ. Coronavirus disease 2019 (COVID-19): a perspective from China. *Radiology*. 2020; 296(2):E15-E25. <https://doi.org/10.1148/radiol.2020200490>
- [10] Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, Liu L, Shan H, Lei C-l, Hui DS. Clinical characteristics of 2019 novel coronavirus infection in China. *MedRxiv* 2020. <https://doi.org/10.1056/NEJMoa2002032>
- [11] Case series studies quality appraisal checklist. <https://www.ihe.ca/research-programs/rmd/cssqac/cssqac-about>
- [12] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA*. 2020;17;323(11):1061-1069. <https://doi.org/10.1001/jama.2020.1585>
- [13] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020 Feb 15;395(10223):497-506. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5)
- [14] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020 Feb 15;395(10223):507-513. [https://doi.org/10.1016/S0140-6736\(20\)30211-7](https://doi.org/10.1016/S0140-6736(20)30211-7)
- [15] Chung M, Bernheim A, Mei X, Zhang N, Huang M, Zeng X, Cui J, Xu W, Yang Y, Fayad ZA, Jacobi A, Li K, Li S, Shan H. . CT imaging features of 2019 novel coronavirus (2019-nCoV). *Radiology*.2020;295:202:207. <https://doi.org/10.1148/radiol.2020200230>
- [16] Chen L, Liu H, Liu W, Liu J, Liu K, Shang J, Deng Y, Wei S. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. *Zhonghua jie he he hu xi za zhi = Zhonghua Jiehe he Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases*. 2020.43:E005-E005. <https://doi.org/10.3760/cma.j.issn.1001-0939.2020.0005>
- [17] Kui L, Fang Y-Y, Deng Y, Liu W, Wang M-F, Ma J-P, Xiao W, Wang Y-N, Zhong M-H, Liu H-G. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. *Chin Med J (Engl)*. 2020 May 5; 133(9): 1025-1031. <https://doi.org/10.1097/CM9.0000000000000744>
- [18] Chang D, Lin M, Wei L, Xie L, Zhu G, Cruz CSD, Sharma LJJ. Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China. *JAMA*. 2020 Mar 17;323(11):1092-1093. <https://doi.org/10.1001/jama.2020.1623>
- [19] COVID-19, Australia: Epidemiology Report 6 (Reporting week ending 19:00 AEDT 7 March 2020). *Commun Dis Intell* (2018) 2020 Mar 11;44. <https://doi.org/10.33321/cdi.2020.44.21..>
- [20] Liu, Yi Shi Li and Zhang, Dongcui and Tang, Shigang and Chen, Haiou and Chen, Liang and He, Xinchun and Tong, Ming and Liu, Meng and Lin, Yihe and Zhu, Baining and Su, Xin, The Epidemiological and Clinical Characteristics of 2019 Novel Coronavirus Infection in Changsha, China (2/10/2020). Available at: SSRN: <https://ssrn.com/abstract=3537093> - <https://doi.org/10.2139/ssrn.3537093>

- [21] Pan F, Ye T, Sun P, Gui S, Liang B, Li L, Zheng D, Wang J, Hesketh RL, Yang L, Zheng C. Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia. *Radiology*. 2020 Jun;295(3):715-721. <https://doi.org/10.1148/radiol.202000370>
- [22] Zhang M, Wang X, Chen Y, Zhao K, Cai Y, An C, Lin M, Mu. Clinical features of 2019 novel coronavirus pneumonia in the early stage from a fever clinic in Beijing. *Zhonghua Jie He He Hu Xi Za Zhi*. 2020 Feb 15;43(0):E013. <https://doi.org/10.3760/cma.j.issn.1001-0939.2020.0013>
- [23] Feng K, Yun Y, Wang X, Yang G, Zheng Y, Lin C, Wang LF. Analysis of CT features of 15 children with 2019 novel coronavirus infection. *Zhonghua Er Ke Za Zhi*. 2020 Feb 16;58(0):E007. <https://doi.org/10.3760/cma.j.issn.0578-1310.2020.0007>
- [24] X F Wang , J Yuan , Y J Zheng, J Chen , Y M Bao , Y R Wang, L F Wang , H Li , J X Zeng , Y H Zhang , Y X Liu , L Liu. Clinical and epidemiological characteristics of 34 children with 2019 novel coronavirus infection in Shenzhen. *Zhonghua Er Ke Za Zhi*. 2020 Feb 17;58(0):E008. <https://doi.org/10.3760/cma.j.issn.0578-1310.2020.0008>
- [25] Yang X , Yu Y, Xu J , Shu H, Xia J , Liu H , Wu Y, Zhang L , Yu Z , Fang M , Yu T , Wang T , Pan S , Zou X , Yuan S, Shang Y . Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med*. 2020 May;8(5):475-481. [https://doi.org/10.1016/S2213-2600\(20\)30079-5](https://doi.org/10.1016/S2213-2600(20)30079-5)
- [26] Wu J, Wu X, Zeng W, Guo D, Fang Z, Chen L, Huang H, Li C. Chest CT findings in patients with coronavirus disease 2019 and its relationship with clinical features. *Invest Radiol*. 2020 May;55(5):257-261. <https://doi.org/10.1097/RLI.0000000000000670>
- [27] Zhao Z, Xie J, Yin M, Yang Y, He H, Jin T, Li W, Zhu X, Xu J, Zhao C, Li L, Li Y, Mengist HM, Zahid A, Yao Z, Ding C, Qi Y, Gao Y, Ma X. Clinical and Laboratory Profiles of 75 Hospitalized Patients with Novel Coronavirus Disease 2019 in Hefei, China. *MedRxiv*. 2020. <https://doi.org/10.1101/2020.03.01.20029785>
- [28] Zhao W, Yu S, Zha X, Wang N, Pang Q, Li T, Li A. Clinical characteristics and durations of hospitalized patients with COVID-19 in Beijing: a retrospective cohort study. *MedRxiv*. 2020. <https://doi.org/10.1101/2020.03.13.20035436>
- [29] Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, Dai J, Sun Q, Zhao F, Qu J, Yan F. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city, Zhejiang, China. *J Infect*. 2020 Apr;80(4):388-393. <https://doi.org/10.1016/j.jinf.2020.02.016>
- [30] Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, Lee M. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. *JAMA*. 2020 Apr 28;323(16):1612-1614. <https://doi.org/10.1001/jama.2020.4326>
- [31] Huang Y, Zhou H, Yang R, Xu Y, Feng X, Gong P. Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan, China. *MedRxiv*. 2020. <https://doi.org/10.1101/2020.02.27.20029009>
- [32] Jian-ya G. Clinical characteristics of 51 patients discharged from hospital with COVID-19 in Chongqing, China. *MedRxiv*. 2020. <https://doi.org/10.1101/2020.02.20.20025536>
- [33] Zhang Jj, Dong X, Cao YY, Yuan Yd, Yang Yb, Yan Yq, Akdis CA, Gao Y. Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China. *Allergy*. 2020;75:1730-1741. <https://doi.org/10.1111/all.14238>
- [34] Yan S, Song X, Lin F, Zhu H, Wang X, Li M, Ruan J, Lin C, Liu X, Wu Q, Luo Z, Fu W, Chen S, Yuan Y, Liu S, Yao J, Lv C. Clinical Characteristics of Coronavirus Disease 2019 in Hainan, China. *MedRxiv*. 2020. <https://doi.org/10.1101/2020.03.19.20038539>
- [35] Wu J, Liu J, Zhao X, Liu C, Wang W, Wang D, Xu W, Zhang C, Yu J, Jiang B, Cao H, Li L. Clinical characteristics of imported cases of COVID-19 in Jiangsu province: a multicenter descriptive study. *Clin Infect Dis*. 2020 Jul 28;71(15):706-712. <https://doi.org/10.1093/cid/ciaa199>
- [36] Xu Y, Li Y-r, Zeng Q, Lu Z-b, Li Y-z, Wu W, Dong S-y, Huang G, Wang X-h. Clinical characteristics of SARS-CoV-2 pneumonia compared to controls in Chinese Han population. *MedRxiv*. 2020. <https://doi.org/10.1101/2020.03.08.20031658>
- [37] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Hui Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020, 395(10229):1054-1062. [https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3)
- [38] Cheng Z, Lu Y, Cao Q, Qin L, Pan Z, Yan F, Yang W. Clinical Features and Chest CT Manifestations of Coronavirus Disease 2019 (COVID-19) in a Single-Center Study in Shanghai, China. *AJR Am J Roentgenol*. 2020 Jul;215(1):121-126. <https://doi.org/10.2214/AJR.20.22959>
- [39] Liu Y, Li J, Liu D, Song H, Chen C, Pei X, Hu Z. Clinical features and outcomes of 2019 novel coronavirus-infected patients with cardiac injury. *MedRxiv*. 2020. <https://doi.org/10.1101/2020.03.11.20030957>
- [40] Liu Y, Sun W, Li J, Chen L, Wang Y, Zhang L, Yu L. Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019. *MedRxiv*. 2020.
- [41] Xu Y, Xu Z, Liu X, Cai L, Zheng H, Huang Y, Zhou L, Huang L, Lin Y, Deng L, Li J, Chen S, Liu D, Lin Z, Zhou L, He W, Liu X, Li Y. Clinical findings in critical ill patients infected with SARS-Cov-2 in Guangdong Province, China: a multi-center, retrospective, observational study. *MedRxiv*. 2020. <https://doi.org/10.1101/2020.03.03.2003066>
- [42] Wang L, He W, Yu X, Hu D, Bao M, Liu H, Zhou J, Jiang HJ. Clinical findings in critical ill patients infected with SARS-Cov-2 in Guangdong Province, China: a multi-center, retrospective, observational study. *MedRxiv*. 2020. <https://doi.org/10.1016/j.jinf.2020.03.019>
- [43] Feng Z, Yu Q, Yao S, Luo L, Duan J, Yan Z, Yang M, Tan H, Ma M, Li T. Early prediction of disease progression in 2019 novel coronavirus pneumonia patients outside Wuhan with CT and clinical characteristics. *MedRxiv*. 2020. <https://doi.org/10.1101/2020.02.19.20025296>
- [44] Qian GQ, Yang NB, Ding F, Ma AHY, Wang ZY, Shen YF, Shi CW, Lian X, Chu JG, Chen L, Wang ZY, Ren DW, Li GX, Chen XQ, Shen HJ, Chen XM. Epidemiologic and clinical characteristics of 91 hospitalized patients with COVID-19 in Zhejiang, China: a retrospective, multi-centre case series. *QJM*. 2020 Jul 1;113(7):474-481. <https://doi.org/10.1093/qjmed/hcaa089>
- [45] Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, Ng O-T, Marimuthu K, Ang LW, Mak TMJJ. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. *JAMA*. 2020; 323:1488-94. <https://doi.org/10.1001/jama.2020.3204>
- [46] Wen Y, Wei L, Li Y, Tang X, Feng S, Leung K, Wu X, Pan X-F, Chen C, Xia JJ. Epidemiological and clinical characteristics of COVID-19 in Shenzhen, the largest migrant city of China. *MedRxiv*. 2020. <https://doi.org/10.1101/2020.03.22.20035246>
- [47] Liao J, Fan S, Chen J, Wu J, Xu S, Guo Y, Li C, Zhang X, Wu C, Mou HJ. Epidemiological and clinical characteristics of COVID-19 in adolescents and young adults. *TIJ*. 2020; 1:100001. <https://doi.org/10.1101/2020.03.10.20032136>
- [48] Chen X, Zheng F, Qing Y, Ding S, Yang D, Lei C, Yin Z, Zhou X, Jiang D, Zuo QJ. Epidemiological and clinical features of 291 cases with coronavirus disease 2019 in areas adjacent to Hubei, China: a double-center observational study. *MedRxiv*. 2020. <https://doi.org/10.1101/2020.03.03.20030353>
- [49] Yang P, Ding Y, Xu Z, Pu R, Li P, Yan J, Liu J, Meng F, Huang L, Shi LJ. Epidemiological and clinical features of COVID-19 patients with and without pneumonia in Beijing, China. *MedRxiv*. 2020. <https://doi.org/10.1101/2020.02.28.20028068>
- [50] Liu J, Ouyang L, Guo P, sheng Wu H, Fu P, liang Chen Y, Yang

- D, yu Han X, kun Cao Y, Alwalid OJm: Epidemiological, clinical characteristics and outcome of medical staff infected with COVID-19 in Wuhan, China: A retrospective case series analysis. MedRxiv. 2020. <https://doi.org/10.1101/2020.03.09.20033118>
- [51] Fu H, Xu H, Zhang N, Xu H, Li Z, Chen H, Xu R, Sun R, Wen L, Xie Lm: Association between Clinical, Laboratory and CT Characteristics and RT-PCR Results in the Follow-up of COVID-19 patients. MedRxiv. 2020. <https://doi.org/10.1101/2020.03.19.20038315>
- [52] Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, Fan Y, Zheng CJTLID: Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020;20(4):425-434. [https://doi.org/10.1016/S1473-3099\(20\)30086-4](https://doi.org/10.1016/S1473-3099(20)30086-4)
- [53] Zhao W, Zhong Z, Xie X, Yu Q, Liu J: Relation between chest CT findings and clinical conditions of coronavirus disease (COVID-19) pneumonia: a multicenter study. AJR Am J Roentgenol. 2020; 214:1072-7. <https://doi.org/10.2214/AJR.20.22976>
- [54] Fan H, Zhang L, Huang B, Zhu M, Zhou Y, Zhang H, Tao X, Cheng S, Yu W, Zhu L: Retrospective analysis of clinical features in 101 death cases with COVID-19. MedRxiv. 2020. <https://doi.org/10.1101/2020.03.09.20033068>
- [55] Hu L, Chen S, Fu Y, Gao Z, Long H, Ren H-w, Zuo Y, Li H, Wang J, Xv Q-bJm: Risk factors associated with clinical outcomes in 323 COVID-19 hospitalized patients in Wuhan, China. Clin Infect Dis. 2020;xx(xx):1-10. <https://doi.org/10.1093/cid/ciaa539>
- [56] Zhao X, Liu B, Yu Y, Wang X, Du Y, Gu J, Wu XJCR: The characteristics and clinical value of chest CT images of novel coronavirus pneumonia. Clin Radio. 2020;75(5):335-340. <https://doi.org/10.1016/j.crad.2020.03.002>
- [57] Chen Z, Hu J, Zhang Z, Jiang S, Wang T, Shi Z, Zhang ZJm: Caution: clinical characteristics of COVID-19 patients are changing at admission. Available at SSRN 3546044. 2020. <https://doi.org/10.1101/2020.03.03.20030833>
- [58] Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, Li J, Zhao D, Xu D, Gong QJTL: Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020; 395:809-15. [https://doi.org/10.1016/S0140-6736\(20\)30360-3](https://doi.org/10.1016/S0140-6736(20)30360-3)
- [59] Pung R, Chiew CJ, Young BE, Chin S, Chen MI, Clapham HE, Cook AR, Maurer-Stroh S, Toh MP, Poh CJTL: Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures. Lancet. 2020; 395(10229):1039-1046. [https://doi.org/10.1016/S0140-6736\(20\)30528-6](https://doi.org/10.1016/S0140-6736(20)30528-6)
- [60] Zhu W, Xie K, Lu H, Xu L, Zhou S, Fang SJJmV: Initial clinical features of suspected coronavirus disease 2019 in two emergency departments outside of Hubei, China. J Med Virol. 2020; 92: 1525-1532. <https://doi.org/10.1002/jmv.25763>
- [61] Chen X, Jiang Q, Ma Z, Ling J, Hu W, Cao Q, Mo P, Yang R, Gao S, Gui XJm: Clinical characteristics of hospitalized patients with SARS-CoV-2 and hepatitis B virus co-infection. Virol Sin. 2020:1-4. <https://doi.org/10.1101/2020.03.23.20040733>
- [62] Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC et al: Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382:1708-20. <https://doi.org/10.1056/NEJMoa2002032>
- [63] Xu X, Yu C, Qu J, Zhang L, Jiang S, Huang D, Chen B, Zhang Z, Guan W, Ling ZJEJoNM, et al: Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. Eur J Nucl Med Mol Imaging. 2020:1-6. <https://doi.org/10.1007/s00259-020-04735-9>
- [64] Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, Hu Y, Tao Z-W, Tian J-H, Pei Y-YJN: A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265-9. <https://doi.org/10.1038/s41586-020-2008-3>
- [65] World meters, available from: <https://www.worldometers.info/coronavirus/#countries>
- [66] Hu B, Zeng L-P, Yang X-L, Ge X-Y, Zhang W, Li B, Xie J-Z, Shen X-R, Zhang Y-Z, Wang NJPp: Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus. PLoS Pathog. 2017;13:e1006698. <https://doi.org/10.1371/journal.ppat.1006698>
- [67] Haagmans BL, Al Dhahiry SH, Reusken CB, Raj VS, Galiano M, Myers R, Godeke G-J, Jonges M, Farag E, Diab AJTLid: Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. Lancet Infect Dis. 2014; 14:140-5. [https://doi.org/10.1016/S1473-3099\(13\)70690-X](https://doi.org/10.1016/S1473-3099(13)70690-X)
- [68] Peiris JSM, Chu C-M, Cheng VC-C, Chan K, Hung I, Poon LL, Law K-I, Tang B, Hon T, Chan CJTL: Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003; 361:1767-72. [https://doi.org/10.1016/S0140-6736\(03\)13412-5](https://doi.org/10.1016/S0140-6736(03)13412-5)
- [69] Yu N, Li W, Kang Q, Xiong Z, Wang S, Lin X, Liu Y, Xiao J, Liu H, Deng D, et al: Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study. Lancet Infect Dis. 2020;20(5):559-564. [https://doi.org/10.1016/S1473-3099\(20\)30176-6](https://doi.org/10.1016/S1473-3099(20)30176-6)
- [70] Zumla A, Hui DS, Perlman S: Middle East respiratory syndrome. Lancet. 2015; 386:995-1007. [https://doi.org/10.1016/S1473-3099\(20\)30176-6](https://doi.org/10.1016/S1473-3099(20)30176-6)
- [71] World Health Organization, Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance, 28 January 2020. available from: <https://apps.who.int/iris/handle/10665/330893>
- [72] Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, Zhong W, Hao PJSCLS: Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci. China Life Sci. 2020; 63:457-60. <https://doi.org/10.1007/s11427-020-1637-5>
- [73] Bai Y, Yao L, Wei T, Tian F, Jin D-Y, Chen L, Wang MJJ: Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020; 323:1406-7. <https://doi.org/10.1001/jama.2020.2565>
- [74] Zhang H, Kang Z, Gong H, Xu D, Wang J, Li Z, Cui X, Xiao J, Meng T, Zhou WJB: The digestive system is a potential route of 2019-nCoV infection: a bioinformatics analysis based on single-cell transcriptomes. BioRxiv. 2020. <https://doi.org/10.1101/2020.01.30.927806>

Received on April 14, 2020. Accepted on June 23, 2020.

Correspondence: Mojtaba Sepandi, Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran, - E-mail: msepandi@gmail.com

How to cite this article: Alimohamadi Y, Sepandi M, Taghdir M, Hosamirudsari H. Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis. J Prev Med Hyg 2020;61:E304-E312. <https://doi.org/10.15167/2421-4248/jpmh2020.61.3.1530>

© Copyright by Pacini Editore Srl, Pisa, Italy

This is an open access article distributed in accordance with the CC-BY-NC-ND (Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International) license. The article can be used by giving appropriate credit and mentioning the license, but only for non-commercial purposes and only in the original version. For further information: <https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en>